Tests a ketogenic diet in people with MELAS syndrome
Tests a high-fat, low-carbohydrate diet in people with MELAS, a rare mitochondrial disease.
Key facts
- Who runs it
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Where
- Hangzhou, ChinaSee the site
- Trial code
- Registry title
- Effectiveness of Ketogenic Diet in MELAS Syndrome
- Status
- Not yet recruiting
- People taking part
- 100 people, planned
- Started
- 1 Sept 2023
- Expected to end
- 1 Jun 2038
- Type of study
- Interventional
- Treatments tested
- Ketogenic diet
- Record updated
- 28 August 2023
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with MELAS syndrome who had standard MELAS treatment but are not satisfied with the result, and who choose to try a ketogenic diet.
- Sex
- All sexes can join.
- Disease stage
- MELAS syndrome, meeting the diagnostic criteria of MELAS.
- Earlier treatment
- Must have had standard MELAS treatment and not be satisfied with its effect.
Main reasons for not taking part
- Porphyria or problems with fatty acid transport and oxidation
- Severe salt and mineral (electrolyte) problems in the body
- Severe liver or kidney failure
- Cholesterol above 300mgdl, or abnormal blood clotting
- Acute pancreatitis, an eating disorder, or not tolerating a ketogenic diet
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Patients who meet the diagnostic criteria of MELAS and have received MELAS standard therapy but are not satisfied with the therapeutic effect, and voluntarily underwent ketogenic therapy
Who cannot take part
- Diseases with porphyria and disturbances in fatty acid transport and oxidation, severe electrolyte metabolism abnormalities, severe hemodynamic instability, acute respiratory infections, uncontrolled systemic infections, severe liver and renal failure, cholesterolemia (>300mgdl), abnormal coagulation, acute pancreatitis, eating disorders, ketogenic diet intolerance, significant weight loss, poor compliance
Where in China
- Second Affiliated Hospital, School of Medicine, Zhejiang UniversityHangzhou, ChinaContact: Yao Ding, doctorNo longer taking part
About the trial
What the trial wants to find out
The goal of this clinical trial is to evaluate the effectiveness of ketogenic diet in patients with MELAS syndrome. The main questions it aims to answer are:
Read full original descriptionShow less
Clarify the curative effects of ketogenic diet in the treatment of MELAS disease.
Prevent the aggravation of MELAS disease, and improve the quality of life of patients.
Provide reliable evidence-based medical basis for the clinical application of ketogenic diet in the treatment of MELAS syndrome patients.
The clinical data of the participants treated with ketogenic diet will be collected, including the completion of ketogenic diet and clinical data at the start of treatment and after 1 month, 3 months, 6 months and 12 months
The group in the trial
- self pre-and post-controlTreatment being tested
It is a self pre- and post-control, which compares the outcomes of the ketogenic diet with the status that did not receive ketogenic treatment
Treatment: Ketogenic diet
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Clinical Trial of Ketogenic Diet in the Treatment of Mitochondrial Encephalomyopathy With Lactic Acidosis and Stroke-like Episodes(MELAS)
- Plain-language title
- Tests a ketogenic diet in people with MELAS syndromeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 28 August 2023